TO: All Renal Dialysis Facility Providers
Medicare Crossover Changes:
Effective February 1, 2011, renal dialysis crossover claims will be received from Medicare and will be processed by Medicaid for all renal dialysis providers.
*Note: Crossover claims with Dates of Service prior to January 1, 2011 that crossover from Medicare will not pay correctly. These crossover claims must be electronically submitted through the previous claim submission process to Medicaid.
Medicare claims billed by renal dialysis providers will cross over directly from Medicare and will be processed by Medicaid. Providers are limited to the following codes on Medicare crossover claims. Future Medicare revisions may require code updates to this table:
|
Revenue Codes |
Condition Codes |
Procedure Code |
Description |
|
821, 881 |
71, 72,73, 74, 76
|
90999 |
Hemodialysis, home hemodialysis, self care training, home hemo training and ultrafiltration. |
|
831, 841, 851
|
74 |
90945 |
Dialysis procedure other than hemodialysis |
|
831, 841, 851
|
73 |
90993 |
Dialysis training, patient, including helper. |
|
634,<10,000 635, >or = 10,000 |
|
Q4081 |
Injection epogen |
|
636 |
|
J0882 |
Darbopoetin alfa, injection |
|
636 |
|
Appropriate Injectable Codes |
Injectable Drugs |
|
250 |
|
Appropriate NDC Codes (No HCPCS) |
PO Drugs |
|
31X, 921 |
|
Appropriate Lab Codes |
Labs |
|
270 |
|
A4697, A4913 (IV) |
Supply/Admin |
|
771 |
|
Appropriate vaccine HCPCS |
Vaccine |
Medicaid Changes:
All Medicaid services beginning with dates of service January 1, 2011, and thereafter, must be billed according to the following policy. Medicaid’s new requirements mirror Medicare’s as closely as possible.
|
Revenue Codes |
Condition Codes |
Procedure Code |
Description |
|
821 |
71 |
90999 |
Hemodialysis, limited to 156 units per year. |
|
831, 841, 851 |
|
90945 |
Dialysis procedure other than hemodialysis. |
|
831, 841, 851
|
73, 74 |
90993 |
Dialysis training, patient, including helper. Limited to 12 per lifetime. |
|
634,<10,000
635, >or = 10,000 |
|
Q4081* |
Injection epogen |
|
636 |
|
J0882* |
Darbopoetin alfa, injection |
|
636 |
|
Injectable Codes |
See Alabama Medicaid Injectable Drug Listing in appendix H for covered injectable drugs. |
*EPO and Aranasp Monitoring Policy:
Medicaid is requiring providers include the GS modifier, the ED modifier, or the EE modifiers in mirroring Medicare’s policy, refer to Chapter 8 of the Medicare Claims Processing Manual for further definition. These modifiers will be considered ‘informational only’ when billed to Medicaid and no reductions in payment will be made for straight Medicaid claims. Medicaid expects the provider to adhere to the strict definitions defined below:
|
GS |
Dosage of EPO or Darbopoetin Alfa has been reduced and maintained in response to hematocrit or hemoglobin level. |
|
ED |
The hematocrit level has exceeded 39.0% (or hemoglobin 1evel has exceeded 13.0g/dL) 3 or more consecutive billing cycles immediately prior to and including the current billing cycle |
|
EE |
The hematocrit level has exceeded 39.0% (or hemoglobin level has exceeded 13.0g/dL) less than 3 consecutive billing cycles immediately prior to and including the current billing cycle. |
Providers may contact Jerri Jackson, RN, BSN, at 334-242-5630 or e-mail at jerri.jackson@medicaid.alabama.gov if you have any questions.